secwatch.observer — SEC 8-K summary
======================================

Issuer:     CNS Pharmaceuticals, Inc. (CNSP)
CIK:        0001729427
Form:       8-K
Filed at:   2023-08-15T23:59:59+00:00
Accession:  0001683168-23-005787
Event type: other_material
Sentiment:  neutral
Materiality: 0.25
Item codes: 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CNS Pharma amends bylaws; reduces quorum, eliminates written consent
--------------------------------------------------------------------

- Reduced stockholder quorum from a majority to one-third of shares outstanding.
- Eliminated action by written consent of stockholders; all actions require a meeting.
- Clarified vote standard: majority of votes cast (excl. abstentions) for most matters; plurality for directors.
- Adds requirement that nominating persons comply with Rule 14a-19 for proxy solicitations.
- Director removal requires two-thirds of voting power; other technical edits and conforming changes.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1729427/000168316823005787/0001683168-23-005787-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1729427/000168316823005787/cns_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-23-005787

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer